119 related articles for article (PubMed ID: 25217986)
1. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
3. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W
BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.
Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ; Cheng Y
J Gastrointest Cancer; 2024 Jun; 55(2):924-931. PubMed ID: 38470522
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study.
Zhong C; Zhang YF; Huang JH; Xiong CM; Wang ZY; Chen QL; Guo RP
BMC Cancer; 2018 Jun; 18(1):643. PubMed ID: 29879928
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Mulyadi R; Hasan I; Sidipratomo P; Putri PP
J Egypt Natl Canc Inst; 2024 May; 36(1):18. PubMed ID: 38797810
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma.
Chen MY; Juengpanich S; Hu JH; Topatana W; Cao JS; Tong CH; Lin J; Cai XJ
World J Gastroenterol; 2020 Mar; 26(10):1042-1055. PubMed ID: 32205995
[TBL] [Abstract][Full Text] [Related]
10. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study.
Zhang K; Mu L; Ren Y; Jiang T
Eur J Radiol; 2023 Oct; 167():111092. PubMed ID: 37708678
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study.
Guo Y; Wu J; Liang L; Zhu K; Zhou J; Lin L; Chen Y; Cao B; He M; Lian H; Huang W; Cai M
Cancer Imaging; 2023 Sep; 23(1):91. PubMed ID: 37749616
[TBL] [Abstract][Full Text] [Related]
12. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.
He C; Zhang Y; Lin X
J Gastrointest Surg; 2018 Jun; 22(6):989-997. PubMed ID: 29435900
[TBL] [Abstract][Full Text] [Related]
13. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
Liu X; Li H; Wang F; Su K; He B; He J; Zhong J; Han Y; Li Z
BMC Gastroenterol; 2023 Sep; 23(1):299. PubMed ID: 37670232
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
15. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study.
Shiba S; Shibuya K; Katoh H; Kaminuma T; Miyazaki M; Kakizaki S; Shirabe K; Ohno T; Nakano T
Radiat Oncol; 2019 Aug; 14(1):137. PubMed ID: 31375120
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.
Lu W; Jin XL; Yang C; Du P; Jiang FQ; Ma JP; Yang J; Xie P; Zhang Z
Cancer Biol Ther; 2017 Jun; 18(6):433-438. PubMed ID: 28548587
[TBL] [Abstract][Full Text] [Related]
18. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.
Gray SH; White JA; Li P; Kilgore ML; Redden DT; Abdel Aal AK; Simpson HN; McGuire B; Eckhoff DE; Dubay DA
J Vasc Interv Radiol; 2017 Feb; 28(2):231-237.e2. PubMed ID: 27939085
[TBL] [Abstract][Full Text] [Related]
19. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
[TBL] [Abstract][Full Text] [Related]
20. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
